https://www.ambergen.com/wp-content/uploads/logo-retina.png 0 0 Kenneth Rothschild https://www.ambergen.com/wp-content/uploads/logo-retina.png Kenneth Rothschild2016-09-27 13:27:082016-11-10 12:44:44AmberGen awarded 3-year Phase II SBIR grant from NIH-NIGMS to develop Bead-AMS™ for screening on- and off-target drug binding on a proteome-wide scale
Get in Touch
313 Pleasant St.
Watertown, MA 02472
- AmberGen receives US Patent 9,910,034 increasing its broad coverage on PC-PURE™ photo-affinity biomarker purification and enrichment technology for improving the accuracy of diagnostic testing March 2018
- Paper published in PLOS ONE in collaboration with Boston Children’s Hospital “Photocleavage-based affinity purification of biomarkers from serum: Application to multiplex allergy testing” describing application of AmberGen’s PC-PURE™ to highly multiplex in vitro allergy testing (AllerBead™) February 2018